Immediate Postoperative Care and Potential Complications

  • D. K. C. Cooper
  • N. M. Lidsky


The immediate postoperative care of a patient who has undergone heart transplantation, whether it be orthotopic or heterotopic, is similar to that of any patient who has undergone open-heart surgery. Precautions need to be taken, however, to minimize the risk of infection, and in general in the first few postoperative days there is greater concern over potential pump dysfunction and chronotropic inadequacy when compared with other cardiac surgical procedures. Maintenance immunosuppressive therapy is begun immediately before the operation and is continued afterwards.


Ethacrynic Acid Donor Heart Orthotopic Heart Transplant Intravenous Ganciclovir Undergo Heart Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greeley WJ, Leslie JB, Reves JG, Watkins WD. Eicosanoids (prostaglandins) and the cardiovascular syslcm. J Cardiac Surg. 1986;1:357.CrossRefGoogle Scholar
  2. 2.
    Fonger JD, Borkon AM, Baumgartner WA et al.: Acute right heart failure following heart transplanlation: improvement with prostaglandin E1 and right ventricular assist. J Heart Transplant. 1986;5:317.PubMedGoogle Scholar
  3. 3.
    Armitagc JM, Hardesty RL, Griffith BP. Prostaglandin E1: an effective treatment of right heart failure after orthotopic hearl transplantation. J Heart Transplant. 1987;6:348.Google Scholar
  4. 4.
    Ferreira SH, Vane JR. Prostaglandins: their disappearance from and release into the circulation. Nature. 1967;216:868.PubMedCrossRefGoogle Scholar
  5. 5.
    Gorman RR. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors. Adv Prostaglandin Thromboxane Leukotriene Res. 1980;6:417.Google Scholar
  6. 6.
    Mathe AA. Prostaglandins and the lung. In: Ramwell PW. editor. The prostaglandins, Vol. 3. New York: Plenum Press; 1977:169.Google Scholar
  7. 7.
    Bremner WF, Taylor KM. Baird S et al: Hypothalamo-pituitary-thyroid axis function during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1978;75:392.PubMedGoogle Scholar
  8. 8.
    Robuschi G, Medici D. Fesani F et al. Cardiopulmonary bypass:’ a low T4 and T3 syndrome’ with blunted thyrolropin (TSH) response to thyrotropin-releasing hormone (TRH). Hormone Res. 1986;23:151.PubMedCrossRefGoogle Scholar
  9. 9.
    Taniguchi S, Cooper DKC. The potential role of thyroid hormone substitutes in cardiac surgery and transplantation. Asia Pacific J Thorac Cardiovasc Surg. 1996;5:40.CrossRefGoogle Scholar
  10. 10.
    Novitzky D, Human PA, Cooper DKC. Inotropic effect of iriiodothyronine (T3) following myocardial ischemia and cardiopulmonary bypass. I. An experimental study in pigs. Ann Thorac Surg. 1988;45:50.PubMedCrossRefGoogle Scholar
  11. 11.
    Norman DJ, lllingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. (Letter) N Engl J Med. 1988;318:46.PubMedCrossRefGoogle Scholar
  12. 12.
    East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. (Letter) N Engl J Med. 1988;318:47.PubMedCrossRefGoogle Scholar
  13. 13.
    Thompson CB, June CH, Sullivan KM, Thomas F.D. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984;2:1116.PubMedCrossRefGoogle Scholar
  14. 14.
    Schmitz N, Eulen HH, Loffler H. Hypomagnesaemia and cyclosporin toxicity. (Letter) Lancet. 1985;1:103.Google Scholar
  15. 15.
    Ross D. Report of a heart transplant operation. Am J Cardiol. 1968;22:838.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • D. K. C. Cooper
  • N. M. Lidsky

There are no affiliations available

Personalised recommendations